Vaccine Manufacturing Intern

Trump administration reaches diesel supply agreement with Russia ahead of US midterm elections. US President Donald Trump and Russian President Vladimir Putin have reached an agreement to release Russian diesel fuel into American and international markets in an effort to lower energy prices before November's midterm elections. The arrangement has drawn scrutiny over its implications for sanctions against Russia and the continuing war in Ukraine. Iranian Forces Target Strait of Hormuz Shipping in Reported Effort to Influence US Elections Iranian military and allied forces are reportedly using new tactics against commercial shipping in the Strait of Hormuz, with the stated aim of driving up global oil prices and increasing political pressure ahead of the US midterm elections. The activity raises concerns about maritime security and energy supplies along a critical international shipping route. Federal Judge Extends Order Protecting White House Access for CNN, Politico and MS NOW A US federal judge has extended a preliminary injunction preventing the Trump administration from revoking White House press credentials held by reporters from CNN, Politico and MS NOW. The ruling preserves journalists' access while recognizing the government's authority to protect classified national security information. US Regulators Fine Bank of America $1.2 Billion Over Financial Compliance Failures Federal regulators have imposed a $1.2 billion penalty on Bank of America over failures to monitor and report suspicious financial activity. The enforcement action focuses on shortcomings in the bank's compliance procedures and underscores regulatory scrutiny of financial crime prevention. US Justice Department Investigates Suspected Espionage Device Found in OpenAI Conference Room Federal investigators are examining an encrypted recording device reportedly discovered inside a television in an executive conference room at OpenAI. The investigation centers on potential corporate espionage and raises questions about the security of sensitive information within the artificial intelligence company. Trump Suggests Canada Could Become 51st US State, Drawing Canadian Opposition US President Donald Trump has suggested during a campaign rally in San Antonio, Texas, that Canada could eventually become America's 51st state, citing trade relations between the two countries. The remarks prompted objections from Canadian officials and renewed diplomatic controversy. US Ambassador Kimberly Guilfoyle Resigns From Post in Greece Following White House Request Kimberly Guilfoyle has resigned as US ambassador to Greece after the White House requested her departure following a series of damaging reports. Her resignation leaves the State Department seeking new leadership for its diplomatic mission in Athens. Merck Opens $550 Million Pharmaceutical Research Facility in Pennsylvania US pharmaceutical company Merck has inaugurated a $550 million bioanalytical research and development facility in West Point, Pennsylvania. The investment expands the company's domestic research infrastructure and supports advanced pharmaceutical development in the region.

Healthcare stocks are rebounding in 2026, led by Merck and AbbVie. Merck shares have climbed 39% and AbbVie's 24%, against about 12% for the S&P 500. Merck's second-quarter revenue rose 5% to $16.6 billion, beating Wall Street estimates. Keytruda sales hit $8.4 billion, though the drug will likely lose patent exclusivity by 2028. A subcutaneous version, Keytruda Qlex, may help retain market share. Merck's forward dividend yield is 2.3%. AbbVie's revenue grew 10.2% to almost $17 billion, with adjusted earnings per share up 22.9% to $3.65. Skyrizi and Rinvoq sales each rose about 24%, and neither faces US competition until 2033 and 2037 respectively. AbbVie has raised its dividend for 54 straight years, including its time as part of Abbott Laboratories.

What's going on with Moderna stock Monday? Stock score locked: want to see it? Benzinga Rankings give you vital metrics on any stock - anytime. Moderna Inc. (NASDAQ:MRNA) shares are trading higher Monday as investors position ahead of detailed Phase 3 melanoma data for its personalized cancer therapy this Saturday and after BofA raised its price target. Traders move into Moderna ahead of Saturday's Phase 3 melanoma data at ESMO. According to Investing.com, the main driver is Saturday's Presidential Symposium at the ESMO Congress in Madrid, where Moderna and Merck will present full results from the Phase 3 INTerpath-001 trial at 10:30 a.m. ET on Oct. 24. The trial tested intismeran autogene plus Keytruda against Keytruda alone in 1,137 patients with resected stage IIB-IV melanoma. In August, the partners said it met its endpoints of recurrence-free and distant metastasis-free survival but didn't release detailed results, including overall survival. Moderna will host an investor webcast at 1 p.m. ET the same day. Jefferies expects peak unadjusted sales in melanoma alone to top $3 billion. BofA raises its target, and the stock rebounds from Friday's drop off its 52-week high. BofA raised its price target on Moderna to $220 from $200 and kept a Neutral rating. The stock is also rebounding after falling nearly 10% Friday from its 52-week high of $242.29, a drop attributed to profit-taking after a rally of more than 600% this year. Investing.com said the stock's addition to the Nasdaq-100 on October 9 continues to support shares through demand from index funds, and that BioNTech and Pfizer were broadly flat, which suggests the move is specific to Moderna and not a sector rotation. The broader market was also higher, with the Nasdaq up about 1% and the S&P 500 up about half a percent. Moderna reports third-quarter results November 6. Moderna shares climb higher. MRNA Price Action: At the time of publication, Moderna shares are trading 4.40% higher at $227.61, according to data from Benzinga Pro. This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors. Posted In: Beat The Market With Premarket News and Trade Signals